price apr usd
track grow slightli
baxter remain top med-tech pick healthi result prospect
commentari morn call highli support view
compani rel well-posit weather storm five
six major segment see increas demand result pandem
end-market fundament remain healthi across busi
includ all-import renal medic deliveri
busi compani provid guidanc light
myriad near-term uncertainti manag comment call april/
may like repres trough recoveri start manifest june
earnestli back half year direct consist
thesi
long-term outlook baxter likewis compel multipl driver
upsid potenti game-chang theranova hemodialyz structur
trend propel strong pd patient growth continu share captur infus
pump among notabl think result acceler organ
revenu growth forecast period reaffirm buy rate one-
bull defens busi see spike demand
other weak overal portfolio still grow revenu
challeng period covid beyond multipl revenu driver
lead revenu acceler arent price
bear outperform peer sourc fund investor
prepar portfolio rebound trade lack share repo show
manag concern trend revenu still grow
expens elev due covid keep repo plan
tact
net-net believ fill multipl bucket within portfolio today
defens across broadli numer area like energi airlin
hospit restaur face sever impact recoveri
uncertain investor start deploy capit aggress rebound
deutsch bank seek busi compani cover research report thu investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis disclosur analyst certif locat
distribut gmt
trade think multipl lever revenu ep upsid attract
new capit three lever think organ revenu acceler
bp els find level revenu acceler larg
given mix end market compani compet case
hold market-lead posit baxter actual see increas demand five
six major segment result except advanc
surgeri moratorium elect surgeri begin mid-march
weigh sale key product sale total cc
comfort ahead forecast street manag
estim total compani benefit though notabl
even exclud uplift oper growth would still
come upper end guidanc rang underscor underli
health busi fundament
 segment sale benefit order million
mainli due stock purchas pd product china earli
million neg impact revaclear suppli constraint
shift manufactur line theranova
 hsd growth pd reflect continu strength new patient add us
growth even stronger howev new pd patient growth
actual slow quarter given requir undergo pd
cathet insert procedur paus elect procedur late
quarter neg impact volum forese potenti
much meaning though underli pd growth remain
healthi nonetheless remind disproportion lever
higher-growth pd segment compani gener two-
third segment sale thank global share contrast
compani share hd segment rel much modest
global though hd bullish outlook theranova present anoth
meaning multi-year tailwind renal segment
 potenti fluiditi around time aakhi mileston due
pandem though meaning delay unlik continu expect
theranova fda approv come month like tpni
design add-on payment effect januari baxter
continu work provid shift patient
home set consist object aakhi
 segment invest remain signific plan unchang
includ capac expans capital-expenditure theranova ahead us approv
potenti tpni design convers exist
revaclear product line abl manufactur dialyz
well expand total dialyz output capabl result theranova
output capabl ultim increas million unit versu
mid-/high-singl digit million current even higher time
increas demand high-volum product like iv
solut mini-bag boost segment sale million
likewis expect uplift
 continu momentum spectrum iq evo iq infus pump
placement manag note call engag
discuss fda regard emerg use author
novum iq infus pump light pandemic-driven increas
custom demand could add bax recent momentum
pump instal novum iq alreadi approv sever ou
 hurrican season approach underli demand remain
heighten due pandem manag highli confid integr
suppli chain abil meet custom need even end demand
increas even come month
 db data point iv solut price declin though
strongli suspect due increment volum pandem
compani work custom face unpreced financi
pressur given mani recent larg contract win busi
fundament chang price would therefor seem highli unlik
 quantifi call presum segment sale includ
inorgan contribut order million cheetah medic
close octob
 drug purchas benefit segment perform
 driver includ continu momentum gener inject uptick
pharmaci compound biz
cyclophosphamid strength
 still us perform expect rel underwhelm
result reduc custom consumpt inhal anesthet due
deferr elect surgeri begin mid-march impact
much pronounc
 segment sale neg impact estim million
late-quart plummet elect surgeri volum us eu
segment sale hit significantli greater
 still segment sale came comfort ahead estim thank
contribut seprafilm deal close valentin day
contribut million inorgan sale period
account model
 addit segment result benefit on-going
competitor hemostat suppli disrupt continu provid boost
recothrom sale
 manag indic segment sale growth benefit
pandem impli revenu uplift million
 demand prismax prismaflex intern system
consum increas dramat given mani
infect patient present icu sever lung function
compromis often subsequ progress acut renal failur
icu manag note call estim patient
sever ill develop aki note unclear point
mani patient proceed becom chronic dialysi depend
 quarter fda grant eua clearanc oxiri baxter novel
sepsi manag filter featur heparin coat
therefor use simultan crrt remov cytokin
endotoxin treat aki patient sepsi studi
suggest patient admit icu present
sepsi though clear oxiri approv sepsi indic
studi proven almost imposs conduct
 segment sale benefit tune
mani hospit patient requir intens care
 deliv strong perform gener
expect margin prove resili med-tech peer
balanc gross margin bp y/i top-lin
growth manufactur effici expans also driven
depress comp due declin us pharma sale time
advers sale mix sg spend flat dollar basi y/i fell
bp percentag sale yield oper margin
bp street forecast
look ahead see three headwind margin come
quarter expect incur increment covid-rel
cost throughout balanc safeti bonus front-lin
employe capac expans increas freight expens expedit
ship neg mix due pressur advanc surgeri
anesthesia product sale headwind partial off-set
reduct discretionari sg revenu growth expect
remain posit level primarili due advanc
surgeri due aforement expens forecast oper
margin declin rebound sharpli
margin expect bp expans
revenu growth acceler
 revenu forecast move ep
come
price current end previou trade session unless otherwis indic sourc local exchang via reuter bloomberg vendor
inform sourc deutsch bank subject compani sourc disclosur pertain recommend estim made secur primari
subject research pleas see recent publish compani report visit global disclosur look-up page websit http //research db com/research/disclosures/
companysearch asid within report import risk conflict disclosur also found investor
strongli encourag review inform invest
import disclosur requir regul
disclosur mark asterisk may also requir least one jurisdict addit unit state see
import disclosur requir non-u regul explanatori note
within past year deutsch bank and/or affili manag co-manag public privat offer
compani receiv fee
deutsch bank and/or affili receiv compens compani provis invest
bank financi advisori servic within past year
deutsch bank and/or affili expect receiv intend seek compens invest bank
servic compani next three month
deutsch bank and/or affili receiv non-invest bank relat compens compani
within past year
compani client deutsch bank secur inc within past year time receiv
import disclosur requir non-u regul
disclosur mark asterisk may also requir least one jurisdict addit unit state see
import disclosur requir non-u regul explanatori note
within past year deutsch bank and/or affili manag co-manag public privat offer
compani receiv fee
deutsch bank and/or affili receiv compens compani provis invest
bank financi advisori servic within past year
disclosur pertain recommend estim made secur primari subject
research pleas see recent publish compani report visit global disclosur look-up page websit
http //research db com/research/disclosures/companysearch
view express report accur reflect person view undersign lead analyst subject
issuer secur issuer addit undersign lead analyst receiv
compens provid specif recommend view report pito chicker
histor recommend target price bax
equiti rate dispers bank relationship
buy base current month view total share-hold
return tsr percentag chang share price current
price project target price plu pro-ject dividend yield
recommend investor buy stock
sell base current view total share-hold
return recommend investor sell stock
hold take neutral view stock
base time horizon recommend either buy
newli issu research recommend target price
recommendationsbuyholdsellnot ratedsuspend rate analyst longer atdeutsch bankdatesecur target price chang usd kristen target price chang usd pito buy target price chang usd stewart target price chang usd pito chicker april
inform opinion report prepar deutsch bank ag one affili collect deutsch
though inform herein believ reliabl obtain public sourc believ
reliabl deutsch bank make represent accuraci complet hyperlink third-parti websit
report provid reader conveni deutsch bank neither endors content respons
accuraci secur control websit
use servic deutsch bank connect purchas sale secur discuss report
includ discuss anoth commun oral written deutsch bank analyst deutsch bank may act
princip account agent anoth person
deutsch bank may consid report decid trade princip may also engag transact account
custom manner inconsist view taken research report other within deutsch bank
includ strategist sale staff analyst may take view inconsist taken research
report deutsch bank issu varieti research product includ fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type commun may differ
recommend contain other whether result differ time horizon methodolog perspect
otherwis deutsch bank and/or affili may also hold debt equiti secur issuer write analyst
paid part base profit deutsch bank ag affili includ invest bank trade
princip trade revenu
opinion estim project constitut current judgment author date report
necessarili reflect opinion deutsch bank subject chang without notic deutsch bank provid liquid
buyer seller secur issu compani cover deutsch bank research analyst sometim
shorter-term trade idea may inconsist deutsch bank exist long-term rate trade idea
equiti list catalyst call research websit http //research db com/research/ found
gener coverag list also cover compani page catalyst call repres high-convict belief analyst
stock outperform under-perform market and/or specifi sector time frame less two week
three month addit catalyst call analyst may occasion discuss client
deutsch bank salesperson trader trade strategi idea refer catalyst event may near-
term medium-term impact market price secur discuss report impact may direct
counter analyst current view total return invest return describ herein deutsch bank
oblig updat modifi amend report otherwis notifi recipi thereof opinion forecast estim
chang becom inaccur coverag frequenc chang market condit gener
company-specif econom prospect make difficult updat research defin interv updat sole
discret coverag analyst research depart manag major report publish
irregular interv report provid inform purpos take account particular
invest object financi situat need individu client offer solicit offer buy
sell financi instrument particip particular trade strategi target price inher imprecis
product analyst judgment financi instrument discuss report may suitabl investor
investor must make inform invest decis price avail financi instrument subject
chang without notic invest transact lead loss result price fluctuat factor
financi instrument denomin currenc investor currenc chang exchang rate may advers
affect invest past perform necessarili indic futur result perform calcul exclud
transact cost unless otherwis indic unless otherwis indic price current end previou
trade session sourc local exchang via reuter bloomberg vendor data also sourc
deutsch bank subject compani parti
deutsch research depart independ busi divis detail regard
organiz arrang inform barrier prevent avoid conflict interest respect
research avail websit http //research db com/research/ disclaim
macroeconom fluctuat often account risk associ exposur instrument promis pay
fix variabl interest rate investor long fixed-r instrument thu receiv cash flow increas
interest rate natur lift discount factor appli expect cash flow thu caus loss longer
matur certain cash flow higher move discount factor higher loss upsid surpris
inflat fiscal fund need fx depreci rate among common advers macroeconom shock
receiv counterparti exposur issuer creditworthi client segment regul includ chang asset
hold limit differ type investor chang tax polici currenc convert may constrain currenc
convers repatri profit and/or liquid posit settlement issu relat local clear hous
also import risk factor sensit fixed-incom instrument macroeconom shock may mitig
index contract cash flow inflat fx depreci specifi interest rate common
emerg market index fix may construct lag mis-measur actual move underli variabl
intend track choic proper fix metric particularli import swap market float
coupon rate coupon index typic short-dat interest rate refer index exchang fix coupon
fund currenc differ currenc coupon denomin carri fx risk option swap
swaption risk typic option addit risk relat rate movement
deriv transact involv numer risk includ market counterparti default illiquid risk appropri
product use investor depend investor circumst includ tax posit
regulatori environ natur asset liabil investor take expert legal
financi advic enter transact similar inspir content public risk loss
futur trade option foreign domest substanti result high degre leverag obtain
futur option trade loss may incur greater amount fund initi deposit
theoret unlimit loss trade option involv risk suitabl investor prior buy sell
option investor must review characterist risk standard option http //www optionsclear com/
about/publications/character-risk jsp unabl access websit pleas contact deutsch bank
repres copi import document
particip foreign exchang transact may incur risk aris sever factor includ follow exchang
rate volatil subject larg fluctuat ii valu currenc may affect numer market
factor includ world nation econom polit regulatori event event equiti debt market chang
interest rate iii currenc may subject devalu government-impos exchang control could
affect valu currenc investor secur adr whose valu affect currenc
unless govern law provid otherwis transact execut deutsch bank entiti
investor home jurisdict asid within report import conflict disclosur also found http //
